



## **NexImmune to Present at the 2021 Barclays Global Healthcare Conference**

March 2, 2021

GAITHERSBURG, Md., March 02, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Scott Carmer, Chief Executive Officer, will present a company overview at the virtual 2021 Barclays Global Healthcare Conference on Thursday, March 11, 2021 at 10:55 a.m. Eastern time.

The presentation will be accessible via live webcast by visiting <https://ir.neximmune.com/investors/events-and-presentations>. A replay will be available on the NexImmune website following the presentation.

### **About NexImmune**

NexImmune, based in Gaithersburg, Maryland, is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells to generate a specific, potent and durable immune response that mimics natural biology. For more information, visit [www.neximmune.com](http://www.neximmune.com).

### **Contacts**

#### **Investors:**

Chad Rubin  
Solebury Trout  
646-378-2947  
[crubin@soleburytrout.com](mailto:crubin@soleburytrout.com)

#### **Media:**

Mike Beyer  
Sam Brown Inc. Healthcare Communications  
312-961-2502  
[mikebeyer@sambrown.com](mailto:mikebeyer@sambrown.com)